Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease

被引:708
作者
Bell, Robert D. [1 ,2 ]
Zlokovic, Berislav V. [1 ,2 ]
机构
[1] Univ Rochester, Sch Med & Dent, Ctr Neurodegenerat & Vasc Brain Disorders, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Interdisciplinary Program Dementia Res, Rochester, NY 14642 USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; Neurovascular; Blood-brain barrier; A beta; Clearance; CEREBRAL AMYLOID ANGIOPATHY; MILD COGNITIVE IMPAIRMENT; SERUM RESPONSE FACTOR; RECEPTOR-RELATED PROTEIN-1; CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE-CELLS; A-BETA PEPTIDES; APOLIPOPROTEIN-E; TOPOGRAPHICAL DISTRIBUTION; MICROVASCULAR PATHOLOGY;
D O I
10.1007/s00401-009-0522-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Vascular dysfunction has a critical role in Alzheimer's disease (AD). Recent data from brain imaging studies in humans and animal models suggest that cerebrovascular dysfunction may precede cognitive decline and onset of neurodegenerative changes in AD and AD models. Cerebral hypoperfusion and impaired amyloid beta-peptide (A beta) clearance across the blood-brain barrier (BBB) may contribute to the onset and progression of dementia AD type. Decreased cerebral blood flow (CBF) negatively affects the synthesis of proteins required for memory and learning, and may eventually lead to neuritic injury and neuronal death. Impaired clearance of A beta from the brain by the cells of the neurovascular unit may lead to its accumulation on blood vessels and in brain parenchyma. The accumulation of A beta on the cerebral blood vessels, known as cerebral amyloid angiopathy (CAA), is associated with cognitive decline and is one of the hallmarks of AD pathology. CAA can severely disrupt the integrity of the blood vessel wall resulting in micro or macro intracerebral bleedings that exacerbates neurodegenerative process and inflammatory response and may lead to hemorrhagic stroke, respectively. Here, we review the role of the neurovascular unit and molecular mechanisms in vascular cells behind AD and CAA pathogenesis. First, we discuss apparent vascular changes, including the cerebral hypoperfusion and vascular degeneration that contribute to different stages of the disease process in AD individuals. We next discuss the role of the low-density lipoprotein receptor related protein-1 (LRP), a key A beta clearance receptor at the BBB and along the cerebrovascular system, whose expression is suppressed early in AD. We also discuss how brain-derived apolipoprotein E isoforms may influence A beta clearance across the BBB. We then review the role of two interacting transcription factors, myocardin and serum response factor, in cerebral vascular cells in controlling CBF responses and LRP-mediated A beta clearance. Finally, we discuss the role of microglia and perivascular macrophages in A beta clearance from the brain. The data reviewed here support an essential role of neurovascular and BBB mechanisms in contributing to both, onset and progression of AD.
引用
收藏
页码:103 / 113
页数:11
相关论文
共 105 条
[21]   Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics [J].
de la Torre, JC .
LANCET NEUROLOGY, 2004, 3 (03) :184-190
[22]   LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms [J].
Deane, R ;
Wu, ZH ;
Sagare, A ;
Davis, J ;
Yan, SD ;
Hamm, K ;
Xu, F ;
Parisi, M ;
LaRue, B ;
Hu, HW ;
Spijkers, P ;
Guo, H ;
Song, XM ;
Lenting, PJ ;
Van Nostrand, WE ;
Zlokovic, BV .
NEURON, 2004, 43 (03) :333-344
[23]   Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimer's Disease [J].
Deane, R. ;
Bell, R. D. ;
Sagare, A. ;
Zlokovic, B. V. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (01) :16-30
[24]   RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain [J].
Deane, R ;
Yan, SD ;
Submamaryan, RK ;
LaRue, B ;
Jovanovic, S ;
Hogg, E ;
Welch, D ;
Manness, L ;
Lin, C ;
Yu, J ;
Zhu, H ;
Ghiso, J ;
Frangione, B ;
Stern, A ;
Schmidt, AM ;
Armstrong, DL ;
Arnold, B ;
Liliensiek, B ;
Nawroth, P ;
Hofman, F ;
Kindy, M ;
Stern, D ;
Zlokovic, B .
NATURE MEDICINE, 2003, 9 (07) :907-913
[25]   apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain [J].
Deane, Rashid ;
Sagare, Abhay ;
Hamm, Katie ;
Parisi, Margaret ;
Lane, Steven ;
Finn, Mary Beth ;
Holtzman, David M. ;
Zlokovic, Berislav V. .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (12) :4002-4013
[26]   Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study [J].
Drzezga, A ;
Lautenschlager, N ;
Siebner, H ;
Riemenschneider, M ;
Willoch, F ;
Minoshima, S ;
Schwaiger, M ;
Kurz, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (08) :1104-1113
[27]   Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease [J].
El Khoury, Joseph ;
Toft, Michelle ;
Hickman, Suzanne E. ;
Means, Terry K. ;
Terada, Kinya ;
Geula, Changiz ;
Luster, Andrew D. .
NATURE MEDICINE, 2007, 13 (04) :432-438
[28]   Vascular smooth muscle actin is reduced in Alzheimer disease brain: A quantitative analysis [J].
Ervin, JF ;
Pannell, C ;
Szymanski, M ;
Welsh-Bohmer, K ;
Schmechel, DE ;
Hulette, CM .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2004, 63 (07) :735-741
[29]   Cerebral microvascular pathology in aging and Alzheimer's disease [J].
Farkas, E ;
Luiten, PGM .
PROGRESS IN NEUROBIOLOGY, 2001, 64 (06) :575-611
[30]   Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's disease patients [J].
Fiala, M ;
Lin, J ;
Ringman, J ;
Kermani-Arab, V ;
Tsao, G ;
Patel, A ;
Lossinsky, AS ;
Graves, MC ;
Gustavson, A ;
Sayre, J ;
Sofroni, E ;
Suarez, T ;
Chiappelli, F ;
Bernard, G .
JOURNAL OF ALZHEIMERS DISEASE, 2005, 7 (03) :221-232